Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 29, 2004 W.D. Crotty	Future Looking Up for Flamel As the nanotech/biotech company earns a profit -- keep an eye on two drugs in phase 3 trials.
The Motley Fool July 8, 2004 W.D. Crotty	From Flameout to Bargain Despite its stock decline, there's a lot to like about French biopharmaceutical Flamel.
The Motley Fool March 4, 2005 Rich Duprey	Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails.
The Motley Fool September 6, 2005 Rich Duprey	Flamel's Dubious Future French nanotech pioneer loses deal with TAP Pharmaceuticals for heartburn formulation. There's just too much fog facing this company for investors to see clearly ahead.
The Motley Fool September 27, 2005 Jack Uldrich	A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead.
The Motley Fool June 6, 2005 Rich Duprey	Flamel Inflames Passions The nanotech firm faces a fiery shareholder fight. Is Flamel doing enough to promote its medical technologies? Management says yes, but shareholders disagree. Here's a survey of the battlefield.
The Motley Fool October 25, 2005 Jason Mac Gurn	Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders.
The Motley Fool June 15, 2005 Charly Travers	Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success.
The Motley Fool June 14, 2005 Bill Mann	It's Time for a Change at Flamel A dissident shareholder believes that the French medical tech company's management needs shaking up. Reluctantly, we agree.
The Motley Fool September 20, 2004 Wherrett & Yelovich	Flamel Shot Down The company's nano product loses some of its shine. The stock fell more than 25% after Bristol-Myers Squibb pulled out of its partnership to develop Basulin.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
The Motley Fool April 19, 2004 Rick Aristotle Munarriz	Say Yo to Drugs It will be a busy week for the country's leading drug makers as they post their quarterly earnings.
The Motley Fool May 15, 2008 Brian Lawler	What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority.
The Motley Fool November 2, 2007 Brian Lawler	Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note.
The Motley Fool June 10, 2004 Rich Smith	Does JoS. A. Bank Measure Up? How does the fast-growing clothier hold up to a Hidden Gems appraisal?
The Motley Fool March 5, 2008 Brian Lawler	Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline.
The Motley Fool May 26, 2004 Tom Gardner	Finding Lynch's 10-Baggers There's a method to finding tomorrow's home runs. The author has made it his mission to uncover the best underfollowed, underappreciated companies before Wall Street gets on board.
The Motley Fool August 27, 2007 Rich Duprey	Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed.
The Motley Fool September 14, 2007 Brian Lawler	Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret.
The Motley Fool May 19, 2004 Paul Elliott	The Art of Picking Winners The author explores Hidden Gems stock selection.
The Motley Fool December 21, 2007 Brian Lawler	Flamel Wheeling and Dealing Flamel announces very few details about it's latest deal, this time with German drugmaker Merck KGaA.
The Motley Fool February 9, 2005 Rich Smith	How to Turn $1,000 Into $1 Million There's no reason that it can't happen for you. Save money. Invest it regularly. Let the magic of compounding returns work for you.
The Motley Fool April 28, 2008 Brian Lawler	Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another.
The Motley Fool February 11, 2008 Brian Lawler	No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker.
The Motley Fool June 23, 2005 Bill Barker	History Is Made, for Now At yesterday's annual meeting, Flamel's shareholders made history. All proposals to re-elect the former directors were rejected by voting shareholders.
The Motley Fool December 18, 2006 Brian Lawler	Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely.
The Motley Fool April 21, 2005 Stephen D. Simpson	SurModics' Profitable Ride The company is more of a biotech/pharmaceutical facilitator than a star, but that doesn't mean the profits are any less green. Investors need to approach the stock with their eyes fully open.
The Motley Fool May 25, 2005 Rich Smith	3 Hidden Gems for the Taking Get these stocks before they're hot on Wall Street: Radyne ComStream... Deckers... Portfolio Recovery Associates...
The Motley Fool January 12, 2005 Rich Smith	How to Turn $1,000 Into $1 Million There's no reason that it can't happen for you: Save money. Invest it regularly. Let the magic of compounding returns work for you.
The Motley Fool October 26, 2007 Brian Lawler	Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note.
The Motley Fool May 14, 2007 Brian Lawler	Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note.
The Motley Fool October 29, 2004 Rich Smith	3 Gems for the Taking Mr. Market has already forgotten again that these companies exist, but we haven't. Here are three classic recommendations that no one on Wall Street is watching. Still high quality. Still low price.
The Motley Fool November 3, 2004 Rich Smith	How to Turn $1,000 Into $1 Million There's no reason it can't happen for you. Time's marching on, and that money of yours isn't going to grow itself, uninvested.
The Motley Fool December 8, 2004 Rich Smith	How to Turn $1,000 Into $1 Million There's no reason it can't happen for you. Save money. Invest it regularly. Let the magic of compounding returns work for you.
The Motley Fool October 25, 2007 Brian Lawler	Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note.
The Motley Fool January 28, 2005 Stephen D. Simpson	SurModics Stays in the Hot Spot Medical technology coatings specialist occupies the hazy world between biotech and medical devices. Though priced roughly in line with peers like Flamel or Nektar, the stock trades at almost 10 times sales and even the forward P/E is a robust 26.5.
The Motley Fool November 15, 2007 Brian Lawler	Flamel Now Part of Wacky Lawsuit Hijinks Multiple class action shareholder lawsuits targeting Flamel Technologies are announced, following a failed study of the company's lead drug.
The Motley Fool February 17, 2006 Rick Aristotle Munarriz	Best Small Cap: Blue Nile by a Mile In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: The jewelry maven Blue Nile adds a bit more gold.
The Motley Fool August 5, 2004 Rich Duprey	Nano Says No to IPO Citing "adverse market conditions" Nanosys, a Palo Alto-based nanotechnology start-up, pulled its IPO.
The Motley Fool August 8, 2008 Brian Lawler	Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline.
The Motley Fool July 26, 2007 Brian Lawler	Flamel Gets Stomped by GSK Shares of Flamel fall as its partner doesn't focus on marketing its lead drug.
The Motley Fool January 6, 2005 Rich Duprey	Bristol-Myers Relieves Its Headache The pharmaceutical giant is selling its consumer medicines division. Though the division represents only about 2% of Bristol-Myers' $21 billion sales, the company overall has seen sales falter and its stock decline some 12% last year.
The Motley Fool September 20, 2004 Rich Duprey	Is Unilever Taking a Bath? The consumer products conglomerate warns of lowers sales and profits.
The Motley Fool December 22, 2005 Tim Hanson	The Power of Multibaggers In the battle for home run stocks, slugging percentage trumps batting average. Small caps are a must because they can help put your portfolio far ahead of the market.
The Motley Fool August 30, 2004	Who's in the Dow? Did you realize that the Dow is an average of just 30 companies?
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool January 27, 2005 Wherrett & Yelovich	Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look.
The Motley Fool June 30, 2010 Jordan DiPietro	Foreign Stocks You Can Actually Buy: France Finding French foreign stocks on U.S. indices can be difficult, so here's a start: Alcatel-Lucent... Flamel... France Telecom... Sanofi-Aventis... Toreador Resources... Total... Veolia Environment...
The Motley Fool April 24, 2006 Rich Duprey	CEC Under Pirate Attack Hedge fund activist Pirate Capital takes a large stake in the kid-oriented pizza-and-party operation. Investors, is this good or bad? Take note.
The Motley Fool October 28, 2005 Jack Uldrich	A New Nanotech Fund The PowerShares fund tries to make it easier to invest in nanotech. But the choice of companies could have been better.